Siemens Fonds Invest GmbH Sells 214,932 Shares of Pfizer Inc. (NYSE:PFE)

Siemens Fonds Invest GmbH reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 99.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,625 shares of the biopharmaceutical company's stock after selling 214,932 shares during the period. Siemens Fonds Invest GmbH's holdings in Pfizer were worth $43,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer during the 4th quarter worth about $27,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter worth about $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the fourth quarter valued at about $32,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.51 on Tuesday, hitting $23.51. 56,982,321 shares of the company traded hands, compared to its average volume of 41,026,680. The firm's 50-day simple moving average is $23.56 and its 200 day simple moving average is $25.27. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $133.66 billion, a P/E ratio of 16.67, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.82 EPS. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.32%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.